A Multicentre Surveillance Study to Evaluate the Long-term Safety in Participants who Have Been Previously Treated with 177Lu-IPN01072 in an Ipsen-sponsored Clinical Study

Start Date26 Jan 2022

Sponsor / Collaborator

Ariceum Therapeutics GmbHStartup

NCT04997317 / RecruitingEarly Phase 1IIT

Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-Satoreotide (PROMENADE-Study)

Meningiomas are known to be the most frequent intracranial neoplasms and account for approx. 25-33% of all intracranial tumours.Targeted radionuclide therapy with radiolabelled somatostatin analogues, also called Peptide Receptor Radionuclide Therapy (PRRT), has proven to be an effective treatment in metastatic intestinal neuroendocrine tumours and is currently used in advanced, recurrent or progressive meningiomas with promising results. In this study, the therapeutic index of a standard and newly developed radiolabelled somatostatin antagonist will be evaluated and compared in PRRT. In a second step, safety and efficacy of the latter will be assessed.

Start Date21 Apr 2021

Sponsor / Collaborator

Universitätsspital Basel

[+1]

NCT03773133 / TerminatedPhase 1/2

A Multicentre, Open-Label Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

This study consists of two phases. The phase I study is designed to investigate the safety and tolerability of Satoreotide tetraxetan following fractionated i.v. administrations in pre-treated subjects with locally advanced or metastatic cancers expressing sstr2 as identified by Satoreotide trizoxetan Positron Emission Tomography (PET/CT) scans. This phase will encompass both radioactivity escalation and peptide mass dose evaluation. Phase II will assess the efficacy of Satoreotide tetraxetan in subjects in selected indications, in a basket design.

Start Date14 May 2019

Sponsor / Collaborator

Ipsen SA

100 Clinical Results associated with 177Lu-Satoreotide tetraxetan

100 Translational Medicine associated with 177Lu-Satoreotide tetraxetan

100 Patents (Medical) associated with 177Lu-Satoreotide tetraxetan

Literatures (Medical) associated with 177Lu-Satoreotide tetraxetan

03 Jun 2024·MOLECULAR PHARMACEUTICS

Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma

Article

Author: Ho, Khanh-Van ; Li, Longbo ; Iweha, Ejike ; Pun, Michael D ; Gallazzi, Fabio ; Watkinson, Lisa ; Anderson, Carolyn J ; Carmack, Terry L

Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survival, it is an ideal candidate for the imaging and delivery of therapeutic payloads. An analog of [¹⁷⁷Lu]Lu-labeled-LLP2A was previously investigated as a therapeutic agent in melanoma tumor-bearing mice, resulting in only a modest improvement in tumor growth inhibition, likely due to rapid clearance of the agent from the tumor. To improve the pharmacokinetic profile, DOTAGA-PEG₄-LLP2A with a 4-(p-iodophenyl)butyric acid (pIBA) albumin binding moiety was synthesized. We demonstrate the feasibility of this albumin binding strategy by comparing in vitro cell binding assays and in vivo biodistribution performance of [¹⁷⁷Lu]Lu-DOTAGA-PEG4-LLP2A ([¹⁷⁷Lu]Lu-1) to the albumin binding [¹⁷⁷Lu]Lu-DOTAGA-pIBA-PEG₄-LLP2A ([¹⁷⁷Lu]Lu-2). In vitro cell binding assay results for [¹⁷⁷Lu]Lu-1 and [¹⁷⁷Lu]Lu-2 showed K_d values of 0.40 ± 0.07 and 1.75 ± 0.40 nM, with similar B_max values of 200 ± 6 and 315 ± 15 fmol/mg, respectively. In vivo biodistribution data for both tracers exhibited specific uptake in the tumor, spleen, thymus, and bone due to endogenous expression of VLA-4. Compound [¹⁷⁷Lu]Lu-2 exhibited a much longer blood circulation time compared to [¹⁷⁷Lu]Lu-1. The tumor uptake for [¹⁷⁷Lu]Lu-1 was highest at 1 h (∼15%ID/g) and that for [¹⁷⁷Lu]Lu-2 was highest at 4 h (∼23%ID/g). Significant clearance of [¹⁷⁷Lu]Lu-1 from the tumor occurs at 24 h (<5%ID/g) while[¹⁷⁷Lu]Lu-2 is retained for greater than 96 h (∼10%ID/g). An efficacy study showed that melanoma tumor-bearing mice receiving compound [¹⁷⁷Lu]Lu-2 given in two fractions (2 × 14.8 MBq, 14 days apart) had a greater median survival time than mice administered a single 29.6 MBq dose of compound [¹⁷⁷Lu]Lu-1, while a single 29.6 MBq dose of [¹⁷⁷Lu]Lu-2 imparted hematopoietic toxicity. The in vitro and in vivo data show addition of pIBA to [¹⁷⁷Lu]Lu-DOTAGA-PEG₄-LLP2A slows blood clearance for a higher tumor uptake, and there is potential of [¹⁷⁷Lu]Lu-2 as a theranostic in fractionated administered doses.

01 Dec 2023·European Journal of Nuclear Medicine and Molecular Imaging

A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

Article

Author: Navalkissoor, Shaunak ; Pennestri, Daniele ; Haug, Alexander ; Ansquer, Catherine ; Hicks, Rodney J ; Lenzo, Nat P ; Volteau, Magali ; Nicolas, Guillaume P ; Lassmann, Michael ; Grønbæk, Henning ; Wild, Damian ; Pais, Ben ; McEwan, Alexander ; Beauregard, Jean-Mathieu

Abstract:

Purpose:

We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [177Lu]Lu-satoreotide tetraxetan in 40 patients with previously treated, progressive neuroendocrine tumours (NETs), in which dosimetry was used to guide maximum administered activity.

Methods:

This study was conducted in two parts. Part A consisted of 15 patients who completed three cycles of [177Lu]Lu-satoreotide tetraxetan at a fixed administered activity and peptide amount per cycle (4.5 GBq/300 µg). Part B, which included 25 patients who received one to five cycles of [177Lu]Lu-satoreotide tetraxetan, evaluated different administered activities (4.5 or 6.0 GBq/cycle) and peptide amounts (300, 700, or 1300 μg/cycle), limited to a cumulative absorbed radiation dose of 23 Gy to the kidneys and 1.5 Gy to the bone marrow.

Results:

Median cumulative administered activity of [177Lu]Lu-satoreotide tetraxetan was 13.0 GBq over three cycles (13.1 GBq in part A and 12.9 GBq in part B). Overall, 17 (42.5%) patients experienced grade ≥ 3 treatment‑related adverse events; the most common were lymphopenia, thrombocytopenia, and neutropenia. No grade 3/4 nephrotoxicity was observed. Two patients developed myeloid neoplasms considered treatment related by the investigator. Disease control rate for part A and part B was 94.7% (95% confidence interval [CI]: 82.3–99.4), and overall response rate was 21.1% (95% CI: 9.6–37.3).

Conclusion:

[177Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three cycles, has an acceptable safety profile with a promising clinical response in patients with progressive, SSTR-positive NETs. A 5-year long-term follow-up study is ongoing.

Trial registration:

ClinicalTrials.gov, NCT02592707. Registered October 30, 2015.

01 Dec 2021·Journal of nuclear cardiology : official publication of the American Society of Nuclear CardiologyQ3 · MEDICINE

Imaging inflammation in atherosclerotic plaques, targeting SST2 with [111In]In-DOTA-JR11

Q3 · MEDICINE

Article

Author: van der Steen, Antonius F W ; van der Heiden, Kim ; de Jong, Marion ; Krenning, Boudewijn J ; Meester, Eric J ; Bernsen, Monique R ; de Blois, Erik

Abstract:

Background:

Imaging Somatostatin Subtype Receptor 2 (SST2) expressing macrophages by [DOTA,Tyr3]-octreotate (DOTATATE) has proven successful for plaque detection. DOTA-JR11 is a SST2 targeting ligand with a five times higher tumor uptake than DOTATATE, and holds promise to improve plaque imaging. The aim of this study was to evaluate the potential of DOTA-JR11 for plaque detection.

Methods and Results:

Atherosclerotic ApoE−/− mice (n = 22) fed an atherogenic diet were imaged by SPECT/CT two hours post injection of [111In]In-DOTA-JR11 (~ 200 pmol, ~ 50 MBq). In vivo plaque uptake of [111In]In-DOTA-JR11 was visible in all mice, with a target-to-background-ratio (TBR) of 2.23 ± 0.35. Post-mortem scans after thymectomy and ex vivo scans of the arteries after excision of the arteries confirmed plaque uptake of the radioligand with TBRs of 2.46 ± 0.52 and 3.43 ± 1.45 respectively. Oil red O lipid-staining and ex vivo autoradiography of excised arteries showed [111In]In-DOTA-JR11 uptake at plaque locations. Histological processing showed CD68 (macrophages) and SST2 expressing cells in plaques. SPECT/CT, in vitro autoradiography and immunohistochemistry performed on slices of a human carotid endarterectomy sample showed [111In]In-DOTA-JR11 uptake at plaque locations containing CD68 and SST2 expressing cells.

Conclusions:

The results of this study indicate DOTA-JR11 as a promising ligand for visualization of atherosclerotic plaque inflammation.

News (Medical) associated with 177Lu-Satoreotide tetraxetan

12 Dec 2024

·endpts.com

Daiichi's $150M build in China; BioMarin reveals €60M Irish expansion

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Daiichi Sankyo is investing RMB 1.1 billion ($151.4 million) to build a new ADC facility in Shanghai for its oncology drug products, the company said in a Nov. 29 release. BioMarin Pharmaceutical has budgeted €60 million ($63 million) to expand its facility in Cork, Ireland, to add a new laboratory spanning four floors, the company said Monday. The site already has manufacturing capabilities in drug substance production through to packaging. Vertex has signed a memorandum of understanding with Saudi Arabia’s Ministry of Industry and Mineral Resources to localize gene therapy manufacturing, according to a Wednesday release. The agreement is expected to attract SAR 1 billion ($266 million) to the country over the next five years. EuroAPI’s CEO Ludwig de Mot has resigned . Replacing him effective immediately is chief operating officer David Seignolle, the company said Monday. Viviane Monges, director and chair of the board, has also stepped down and will be replaced by Emmanuel Blin, who joined the board in 2022. The leadership reshuffle comes amid EuroAPI’s broader restructuring . SK pharmteco is bringing together its businesses under one brand, it said Wednesday. SK biotek, SK biotek Ireland, Center for Breakthrough Medicines, Yposkesi, AMPAC Fine Chemicals and AMPAC Analytical will now all be known as SK pharmteco but will still operate individually. NorthStar Medical Radioisotopes is supplying actinium-225 to Ariceum Therapeutics for its investigational cancer asset satoreotide, according to a Wednesday release. Just last week, Ariceum also secured a supply contract for actinium-225 and lutetium-177 with isotope maker Eckert & Ziegler. Nusano will supply the radioisotope lutetium-177 to the Australian radiopharma company GlyTherix, according to a Monday release. Nusano will also supply actinium-225 once its production begins in 2026, as well as other isotopes including zirconium-89, lead-212 and terbium-161. Endo has secured FDA approval to manufacture the vasopressin injection Vasostrict at its new factory in Indore, India, the company said Monday. Production will begin in 2026.

Executive Change

11 Dec 2024

·www.prnewswire.com

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225

NorthStar will supply non-carrier added Actinium-225, a radionuclide, for use with Ariceum's first-in-class radiopharmaceutical drug, satoreotide BERLIN and BELOIT, Wis., Dec. 11, 2024 /PRNewswire/ -- Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing of a supply agreement for the therapeutic medical radioisotope, Actinium-225 (Ac-225). Under the terms of the agreement, NorthStar will provide Ariceum with non-carrier-added (n.c.a.), high purity, Ac-225, a rare and critical isotope that is in high demand, providing Ariceum with an additional clinical source of supply for its evolving pipeline development programs. Ariceum will use NorthStar's Ac-225 to radiolabel its proprietary peptide (SS0110) satoreotide, a first-in-class antagonist of the somatostatin receptor 2 (SSTR2). Satoreotide is being developed as a 'theranostic pair' for the combined diagnosis and targeted radionuclide treatment of multiple indications expressing SSTR2, such as small cell lung cancer (SCLC), pancreatic cancers, Merkel Cell Carcinoma, and other aggressive cancers. Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, commented: "Satoreotide is the first Ac-225 labelled antagonist of the SSTR2 receptor targeting SCLC. The compound is scheduled to enter clinical development in the US as part of a transatlantic trial soon. The compound has demonstrated its potential as a Lutetium-177-labelled version in our ongoing Phase 1b clinical study in end stage-SCLC. Based on NorthStar's industry leadership and commercial expertise in cutting-edge, accelerator-based radioisotope production technology, we believe that they are a reliable partner to meet Ariceum's specific needs. In partnership with NorthStar, we look forward to progressing our clinical studies with Ac-225 and accelerating our future commercialization opportunities as we seek to deliver targeted theranostic treatments for patients." "Ariceum's impressive development portfolio is focused on very aggressive, difficult-to-treat cancers and its early trial results are very exciting," said Frank Scholz, President and Chief Executive Officer of NorthStar. "At NorthStar, our goal is to reduce or eliminate concerns about adequate availability of Ac-225 for clinical trials and patient medicines, which have held back exploration of powerful new pathways to attack these diseases for the millions of patients who today have limited treatment options available. We are proud to use our expertise and capabilities to provide innovative companies like Ariceum with high purity, n.c.a. Ac-225, that will help make potential new treatment therapies a prospect for the benefit of patients." About Ariceum Therapeutics, GmbH Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of 'Marie Curie' whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum's lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), or Merkel Cell Carcinoma (MCC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a 'theranostic pair' for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023. Ariceum Therapeutics, launched in 2021, acquired all rights to satoreotide from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, United Kingdom and United States of America and with activities currently across the globe. Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For further information, please visit . About NorthStar Medical Radioisotopes, LLC (NorthStar) NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar's expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar routinely produces copper-67 (Cu-67) and is poised to be the first commercial-scale producer of non-carrier-added (n.c.a.) actinium-225 (Ac-225). The Company's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. For more information about NorthStar's comprehensive portfolio and patient-focused services, visit: . SOURCE Ariceum Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1License out/inAcquisition

05 Dec 2024

·endpts.com

National Resilience's new CEO; Moderna opens Australian manufacturing site

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. National Resilience is replacing its CEO effective immediately with COO William Marth, who will take over from Rahul Singhvi. Marth previously served as CEO of Curia Global, known then as AMRI, as well as CEO of Teva Pharmaceutical’s US division. Moderna has opened its new mRNA manufacturing facility in Australia within the campus of Monash University. The new site will be able to make 100 million vaccine doses a year, and the first dose is anticipated to be produced next year. Around 140 new “direct” jobs will be created at the site. Reckitt Benckiser is pouring £155 million ($200 million) into a new facility in Wilson, NC, to make its over-the-counter flu and cold drug products, the company said Tuesday. This will be Reckitt’s largest OTC manufacturing site in the US and will create 300 new jobs. CDMO Cambrex is partnering with Eli Lilly’s biotech innovative arm, dubbed Lilly Catalyze360-ExploR&D, to offer its services to Lilly’s biotech partners, according to a Thursday release. Agenus has revealed its planning to make layoffs as a part of its wider plan to reduce costs, the company said Thursday. The company said Monday it is restructuring its manufacturing sites to become a biologics CDMO. Nature’s Toolbox has secured $15 million from JP Morgan to fund the development of its manufacturing platforms to make biomaterials, the company said Wednesday. Altasciences is the manufacturer for several of Metsera’s weight loss candidates, the company said on Nov. 28. The CDMO has produced the biotech’s Phase 1/2 GLP-1 asset, dubbed MET-097i. It is also making two other candidates for Metsera: a long-acting amylin analog (MET-233i) and an oral GLP-1 drug (MET-002). Rallybio is moving its C5 inhibitor into a confirmatory study next year following manufacturing improvements, the company said Monday. After data analysis and changes to the production of the drug, named RLYB116, the study will be completed in the second quarter of 2025. GE Healthcare is gaining full ownership of the radiopharma manufacturer Nihon Medi-Physics by buying Sumitomo Chemical’s 50% stake in the company, according to a Sunday release. The transaction is expected to close early next year. Telix IsoTherapeutics has renewed its supply agreement with clinical-stage radiopharma Plus Therapeutics, according to a Tuesday release. Telix will continue to supply rhenium-186 isotopes for Plus’ lead candidate, obisbemeda, which is being studied for CNS tumours. Eckert & Ziegler is supplying the radiopharma company Ariceum Therapeutics with actinium-225 and lutetium-177 for its lead asset, satoreotide, under study for hard-to-treat cancers. KBI Biopharma will manufacture Alanis Therapeutics’ preclinical antibody that is being investigated for myelodysplastic syndromes and acute myeloid leukemia, according to a Tuesday release. CELLforCURE by SEQENS is partnering with clinical-stage biotech Smart Immune, according to a Tuesday release. The CDMO will make the biotech’s Phase 1/2 asset, SMART101, for acute leukemia or primary immunodeficiencies. NorthX Biologics will make Amarna Therapeutics’ clinical-stage gene therapy called Nimvec AM510, which is being investigated for type 1 diabetes, according to a Tuesday announcement. API manufacturer Antheia will receive $12 million from the US Department of Health and Human Services over two years to manufacture an unnamed pharma ingredient domestically, according to a Tuesday release. Lonza’s ADC company Synaffix has entered a licensing agreement with DNA sequencer Illumina, the companies said Wednesday. Synaffix’s so-called “metal-free clock chemistry” tech will be used by Illumina for its DNA sequencing products. Chemical manufacturer LG Chem is collaborating with microbiology biotech Acies Bio on sustainable commercial production of chemicals in high demand, the companies said Thursday. The UK Health Security Agency has signed a contract with CSL Seqirus to manufacture five million doses of human H5 influenza vaccines for the UK, the agency said Tuesday. The Brazilian research organization Oswaldo Cruz Foundation signed a memorandum of understanding with Belgian companies Quantoom Biosciences and Univercells to boost production of RNA therapeutics in Belgium, according to a Friday release. Gavi, the Vaccine Alliance, is investing $23.4 million to help vaccinate children in Sudan, in partnership with Save the Children and UNICEF, according to a Monday release. The funding will in part be used to improve vaccine storage and cold supply chains. With additional reporting by Katherine Lewin

VaccineExecutive ChangeLicense out/inmRNAClinical Study

100 Deals associated with 177Lu-Satoreotide tetraxetan

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16323

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 2	US	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	AT	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	BE	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	FR	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	DE	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	CH	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	GB	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	US	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	AT	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	BE	Ipsen SA	14 May 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02592707 (Pubmed \| Eur J Nucl Med Mol Imaging)	Phase 1/2	Neuroendocrine Tumors	40	[<sup>177</sup>Lu]Lu-satoreotide tetraxetan	wznmythelz(uvifujfdal) = kbohpdhkhe nxstjpimmt (iyzppfxjna ) View more	-	26 Mar 2024
NCT02592707 (phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan, CTgov)	Phase 1/2	Somatostatin Receptor-Positive Neuroendocrine Tumor	40	177Lu-IPN01072 (Part A: 177Lu-IPN01072 4.5 GBq)	ccokvayqqx(rcucvpbtcc) = pnljeojyvt vhzcvtlgog (poukmvbczm, imedsamrmg - fjbtffvkqu) View more	-	19 Jul 2023
	Phase 1/2	Somatostatin Receptor-Positive Neuroendocrine Tumor	40	GBq+177Lu-IPN01072 (Part B Cohort 1: 177Lu-IPN01072 6 GBq)	ccokvayqqx(rcucvpbtcc) = kfqbqtafhj vhzcvtlgog (poukmvbczm, gdutmbqjlq - auncwqgjbn) View more	-	19 Jul 2023
NCT02592707 (ESMO2020) Manual	Phase 1/2	Neuroendocrine Tumors	35	177Lu-satoreotide tetraxetan	kmwkmvrkqi(psnvuufplq) = 34.3%[lymphopenia/decrease in lymphocyte counts in 6 (17.1%), thrombocytopenia/decrease in platelets count in 5 (14.3%), neutropenia in 2 (5.7%) and anemia in 1 (2.9%)]. No grade 3/4 renal toxicities were reported. faglbqfdjq (sezknejnty )	Positive	20 Sep 2020
SNMMI2016	Not Applicable	-	-	DOTA-JR11 (N.C.A 177Lu)	ofoporsmpe(xjefxebikp) = nbdfmsbmbl vrzsknnjxp (cmpxqeefbm )	-	24 May 2016
SNMMI2016	Not Applicable	-	-	DOTA-JR11 (177Lu/177mLu)	ofoporsmpe(xjefxebikp) = upqbcsekfj vrzsknnjxp (cmpxqeefbm )	-	24 May 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis